NLRP3 and cancer: GL-V9, a small-molecule AMPK activator, could prevent colitis-associated cancer through the induction of mitophagy-mediated NLRP3 inflammasome inhibition [37] or through triggering autophagy-mediated NLRP3 inflammasome degradation [38].